N,N'-ethanediyl-bis-isovaleramide | 10525-47-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N'-ethanediyl-bis-isovaleramide
• 英文别名: N,N'-Aethandiyl-bis-isovaleramid；3-methyl-N-[2-(3-methylbutanoylamino)ethyl]butanamide
• CAS: 10525-47-0
• 化学式: C₁₂H₂₄N₂O₂
• 分子量: 228.335
• InChiKey: UQJZEQKPBNPPKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  盐酸 、 N,N'-ethanediyl-bis-isovaleramide 生成 乙二胺
  参考文献：
  名称：

  Windaus; Doerries; Jensen, Chemische Berichte, 1921, vol. 54, p. 2748

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 钯 作用下， 生成 N,N'-ethanediyl-bis-isovaleramide
  参考文献：
  名称：

  Windaus; Doerries; Jensen, Chemische Berichte, 1921, vol. 54, p. 2748

  摘要：

  DOI：

文献信息

• Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US10039809B2

  公开（公告）日：2018-08-07

  Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

  提供了延长治疗剂半衰期的方法和组合物。改性治疗剂（mTA）由治疗剂、主食和延长半衰期分子组成。本文公开的 mTA 可用于治疗有需要的受试者的疾病或病症。
• Bivalent bromodomain inhibitors and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10913752B2

  公开（公告）日：2021-02-09

  The present invention provides bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V), and (VI). Some bromdomain-containing proteins (e.g., BRD4) have a tandem bromodomain primary structure comprising more than one bromodomain binding site (e.g., BRD4 comprises BD1 and BD2). Bivalent inhibitors of BET bromodomains provided herein can target bromodomains through advantageous multivalent interactions, and can therefore can be to treat diseases or conditions associated with bromodomain-containing proteins. The present also provides pharmaceutical compositions and kits comprising the inventive compounds, as well as methods of using the inventive compounds.

  本发明提供了BET溴域的二价抑制剂，如式(I)、(II)、(III)、(IV)、(V)和(VI)的化合物。某些含溴结构域的蛋白质（如 BRD4）具有串联溴结构域一级结构，包含一个以上的溴结构域结合位点（如 BRD4 包含 BD1 和 BD2）。本发明提供的 BET 溴链的二价抑制剂可通过有利的多价相互作用靶向溴链，因此可用于治疗与含溴链蛋白相关的疾病或病症。本发明还提供了包含本发明化合物的药物组合物和试剂盒，以及使用本发明化合物的方法。
• Colloid and nanosized catalysts in organic synthesis: XIII. Synthesis of 2-R-2-imidazolines catalyzed by copper and iron oxide nanoparticles
  作者：Yu. V. Popov、V. M. Mokhov、I. I. Kalitina

  DOI：10.1134/s1070363216020122

  日期：2016.2

  The reaction of carboxylic acids with ethylenediamine catalyzed by copper or iron oxide nanoparticles proceeds at 80A degrees C with azeotropic water distilling off during 2-8 h to form 2-R-2-imidazolines. Acyl and diacyl derivatives of ethylenediamine are formed in the reaction as side products.
• BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20200172553A9

  公开（公告）日：2020-06-04

  The present invention provides bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V) and (VI). Some bromdomain-containing proteins (e.g., BRD4) have a tandem bromodomain primary structure comprising more than one bromodomain binding site (e.g., BRD4 comprises BD1 and BD2). Bivalent inhibitors of BET bromodomains provided herein can target bromodomains through advantageous multivalent interactions, and can therefore can be to treat diseases or conditions associated with bromodomain-containing proteins. The present also provides pharmaceutical compositions and kits comprising the inventive compounds, as well as methods of using the inventive compounds.
• COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF
  申请人：FOG PHARMACEUTICALS, INC.

  公开号：US20210179665A1

  公开（公告）日：2021-06-17

  The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.